Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Moodys
Johnson and Johnson
AstraZeneca
Dow

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Dinaciclib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Dinaciclib?

Dinaciclib is an investigational drug.

There have been 13 clinical trials for Dinaciclib. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Merck Sharp & Dohme Corp., and AbbVie.

There are three hundred and thirteen US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Dinaciclib
TitleSponsorPhase
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaMerck Sharp & Dohme Corp.Phase 1
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaAbbViePhase 1
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast CancerMerck Sharp & Dohme Corp.Phase 1

See all Dinaciclib clinical trials

Clinical Trial Summary for Dinaciclib

Top disease conditions for Dinaciclib
Top clinical trial sponsors for Dinaciclib

See all Dinaciclib clinical trials

US Patents for Dinaciclib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dinaciclib ⤷  Sign up for a Free Trial Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Sign up for a Free Trial
Dinaciclib ⤷  Sign up for a Free Trial Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Sign up for a Free Trial
Dinaciclib ⤷  Sign up for a Free Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) ⤷  Sign up for a Free Trial
Dinaciclib ⤷  Sign up for a Free Trial Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE) ⤷  Sign up for a Free Trial
Dinaciclib ⤷  Sign up for a Free Trial Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Pharmacyclics LLC (Sunnyvale, CA) ⤷  Sign up for a Free Trial
Dinaciclib ⤷  Sign up for a Free Trial Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Sign up for a Free Trial
Dinaciclib ⤷  Sign up for a Free Trial .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dinaciclib

Drugname Country Document Number Estimated Expiration Related US Patent
Dinaciclib Australia AU2011261185 2030-06-03 ⤷  Sign up for a Free Trial
Dinaciclib Australia AU2015275321 2030-06-03 ⤷  Sign up for a Free Trial
Dinaciclib Australia AU2018204179 2030-06-03 ⤷  Sign up for a Free Trial
Dinaciclib Australia AU2020202752 2030-06-03 ⤷  Sign up for a Free Trial
Dinaciclib Brazil BR112012030625 2030-06-03 ⤷  Sign up for a Free Trial
Dinaciclib Canada CA2800913 2030-06-03 ⤷  Sign up for a Free Trial
Dinaciclib Canada CA3007787 2030-06-03 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Moodys
Johnson and Johnson
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.